WeTrials
Recruiting

A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial

What is this study?

This clinical trial is testing whether taking two targeted cancer drugs together is better than taking just one. Researchers want to see if this combination can help shrink or slow down the growth of certain solid tumors that have a specific protein called HER2.

Who can participate?

You might be able to join if you have a solid tumor (other than breast cancer) with high levels of the HER2 protein. Your eligibility will also depend on specific genetic test results from your tumor.

What will happen?

Participants will take targeted cancer therapy pills, either alone or in combination. You will also have regular check-ups, which include imaging scans, heart tests, and tissue or fluid samples to monitor your health.

Where and when?

This study is currently recruiting patients and takes place at multiple locations across the United States, including in Alabama and Alaska.

Key Points
  • 1Tests targeted cancer drugs to block signals that help cancer grow
  • 2Open to patients with certain HER2-positive solid tumors, excluding breast cancer
  • 3Involves regular check-ups, scans, and heart monitoring for your safety

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Malignant Female Reproductive System NeoplasmMalignant Solid NeoplasmRecurrent Malignant Female Reproductive System NeoplasmRecurrent Malignant Solid Neoplasm

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.